The perspective of caffeine and caffeine derived compounds in therapy

Bratislava Medical Journal

Volumn 116, Issue 9, 2015, Pages 520-530

  Pohanka, M ^a,b  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b MENDEL UNIVERSITY IN BRNO   (Czech Republic)

Author keywords

Adenosine; Alzheimer disease; Caffeine; Dopamine; GABA; Immunity; Parkinson disease; Theobromine; Theophylline

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE RECEPTOR BLOCKING AGENT; ALKALOID; AMINE OXIDASE (FLAVIN CONTAINING); CAFFEINE; PHOSPHODIESTERASE INHIBITOR;

BRAIN; DRUG EFFECTS; HUMAN; NEURODEGENERATIVE DISEASES;

ACETYLCHOLINESTERASE; ALKALOIDS; BRAIN; CAFFEINE; HUMANS; MONOAMINE OXIDASE; NEURODEGENERATIVE DISEASES; PHOSPHODIESTERASE INHIBITORS; PURINERGIC P1 RECEPTOR ANTAGONISTS;

EID: 84953399981     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2015_106     Document Type: Article

References (149)

1. Magalhaes ST, Fernandes FL, Demuner AJ, Picanco MC, Guedes RN. Leaf alkaloids, phenolics, and coffee resistance to the leaf miner leucoptera coffeella (lepidoptera: Lyonetiidae). J Econ Entomol 2010; 103 (4): 1438-1443.
2. Kravchenko LV, Trusov NV, Aksenov IV et al. Effects of green tea extract and its components on antioxidant status and activities of xenobiotic metabolizing enzymes of rats. Vopr Pitan 2011; 80 (2): 9-15.
3. Scoparo CT, de Souza LM, Dartora N, Sassaki GL, Gorin PA, Iacomini M. Analysis of camellia sinensis green and black teas via ultra high performance liquid chromatography assisted by liquid-liquid partition and two-dimensional liquid chromatography (size exclusion x reversed phase). J Chromatogr A 2012; 1222: 29-37.
4. Greenfield M. When america first met china: An exotic history of tea, drugs, and money in the age of sail. Pac Hist Rev 2013; 82 (4): 626-627.
5. Villavicencio-Enriquez L. Agroforestry characterization in traditional and rustic coffee systems in san miguel, veracruz, mexico Rev Chapingo Ser Cienc For Am 2013; 19 (1): 67-80.
6. Han WY, Xu JM, Wei K, Shi RZ, Ma LF. Soil carbon sequestration, plant nutrients and biological activities affected by organic farming system in tea (camellia sinensis (1.) o. Kuntze) fields. Soil Sci Plant Nutr 2013; 59 (5): 727-739.
7. Tavares C, Sakata RK. Caffeine in the treatment of pain. Rev Bras Anestesiol 2012; 62 (3): 387-401.
8. Welsh EJ, Bara A, Barley E, Cates CJ. Caffeine for asthma. Cochrane Database Syst Rev 2010; (1).
9. Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol 2005; 16 (2): 63-77.
10. Choung MG, Hwang YS, Lee MS, Lee J, Kang ST, Jun TH. Comparison of extraction and isolation efficiency of catechins and caffeine from green tea leaves using different solvent systems. Int J Food Sci Technol 2014; 49 (6): 1572-1578.
11. Rai A, Punase KD, Mohanty B, Bhargava R. Evaluation of models for supercritical fluid extraction. Int J Heat Mass Transf 2014; 72: 274-287.
12. Kumar GSS, Seethalakshmi PG, Bhuvanesh N, Kumaresan S. Cocrystals of caffeine with formylphenoxyaliphatic acids: Syntheses, structural characterization, and biological activity. J Mol Struct 2013; 1034: 302-309.
13. Rivara S, Piersanti G, Bartoccini F et al. Synthesis of (e)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual a(2a) antagonists/mao-b inhibitors. J Med Chem 2013; 56 (3): 1247-1261.
14. Cordell GA. Fifty years of alkaloid biosynthesis in phytochemistry. Phytochemistry 2013; 91: 29-51.
15. Ashihara H, Sano H, Crozier A. Caffeine and related purine alkaloids: Biosynthesis, catabolism, function and genetic engineering. Phytochemistry 2008; 69 (4): 841-856.
16. McCarthy AA, McCarthy JG. The structure of two n-methyltransferases from the caffeine biosynthetic pathway. Plant Physiol 2007; 144 (2): 879-889.
17. Negishi O, Ozawa T, Imagawa H.N-methyl nucleosidase from tea leaves Agric Biol Chem1988; 52 (1): 169-175.
18. Koshiishi C, Kato A, Yama S, Crozier A, Ashihara H. A new caffeine biosynthetic pathway in tea leaves: Utilisation of adenosine released from the s-adenosyl-l-methionine cycle. FEBS Lett 2001; 499 (1-2): 50-54.
19. Kato M, Mizuno K. Caffeine synthase and related methyltransferases in plants. Front Biosci 2004; 9: 1833-1842.
20. Skinner TL, Jenkins DG, Foiling J, Leveritt MD, Coombes JS, Taaffe DR. Influence of carbohydrate on serum caffeine concentrations following caffeine ingestion. J Sci Med Sport 2013; 16 (4): 343-347.
21. Mesaros C, Culea M, Iordache AM, Visovan I, Cozar C, Cosma C. A new caffeine test for diagnosis of cirrhosis by gc/ms. Asian J Chem 2010; 22 (5): 3608-3614.
22. Orru M, Guitart X, Karcz-Kubicha M et al. Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology 2013; 67: 476-484.
23. Seng KY, Fun CY, Law YL, Lim WM, Fan W, Lim CL. Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models. J Clin Pharm Ther 2009; 34 (1): 103-114.
24. Bannnister AJ, Schneider R, Kouzarides T. Histone methylation: Dynamic or static? Cell 2002; 109 (7): 801-806.
25. Yubero-Lahoz S, Pardo R, Farre M et al. Changes in cyp1a2 activity in humans after 3, 4-methylenedioxymethamphetamine (mdma, ecstasy) administration using caffeine as a probe drug. Drug Metab Pharmacok 2012; 27 (6): 605-613.
26. Tanaka S, Uchida S, Inui N, Takeuchi K, Watanabe H, Namiki N. Simultaneous lc-ms/ms analysis of the plasma concentrations of a cocktail of 5 cytochrome p450 substrate drugs and their metabolites. Biol Pharm Bull 2014; 37 (1): 18-25.
27. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of cyp1a2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in swedes and koreans. Eur J Clin Pharmacol 2007; 63 (6): 537-546.
28. Wang L, Hu Z, Deng X, Wang Y, Zhang Z, Cheng ZH. Association between common cyp1a2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers. Basic Clin Pharmacol Toxicol 2013; 112 (4): 257-263.
29. Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome p450 activity in human and rat. Pharmacol Rep 2008; 60 (6): 789-797.
30. Gordillo-Bastidas D, Oceguera-Contreras E, Salazar-Montes A, Gonzalez-Cuevas J, Hernandez-Ortega LD, Armendariz-Borunda J. Nrf2 and snail-1 in the prevention of experimental liver fibrosis by caffeine. World J Gastroenterol 2013; 19 (47): 9020-9033.
31. Machado SR, Parise ER, Carvalho L. Coffee has hepatoprotective benefits in brazilian patients with chronic hepatitis c even in lower daily consumption than in american and European populations. Braz J Infect Dis 2014; 18 (2): 170-176.
32. Pohanka M. The effects of caffeine on the cholinergic system. Mini Rev Med Chem 2014; 16 (6): 543-549.
33. Namuslu M, Kocaoglu H, Celik HT et al. Effects of aqueous soybean, mistletoe and red clover extracts on activities of adenosine deaminase and xanthine oxidase enzyme. Brat Med J 2014; 115 (6): 367-371.
34. Gyoneva S, Shapiro L, Lazo C et al. Adenosine a(2a) receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of parkinson's disease. Neurobiol Dis 2014; 67: 191-202.
35. Vincenzi F, Targa M, Romagnoli R et al. Trr469, a potent a(1) adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice. Neuropharmacology 2014; 81: 6-14.
36. Hofer M, Pospisil M, Dusek L, Hoferova Z, Komurkova D. Combined pharmacological therapy of the acute radiation disease using a cyclooxygenase-2 inhibitor and an adenosine a(3) receptor agonist. Cent Eur J Biol 2014; 9 (6): 642-646.
37. Fukunaga AF, Alexander GE, Stark CW. Characterization of the analgesic actions of adenosine: Comparison of adenosine and remifentanil infusions in patients undergoing major surgical procedures. Pain 2003; 101 (1-2): 129-138.
38. Joulia F, Coulange M, Lemaitre F et al. Plasma adenosine release is associated with bradycardia and transient loss of consciousness during experimental breath-hold diving. Int J Cardiol 2013; 168 (5): E138-E141.
39. Sullivan GW, Luong LS, Carper HT, Barnes RC, Mandell GL. Methylxanthines with adenosine alter tnf-alpha-primed pmn activation. Immunopharmacology1995; 31 (1): 19-29.
40. Chan ESL, Fernandez P, Cronstein BN. Adenosine in inflammatory joint diseases. Purinergic Signal 2007; 3 (1-2): 145-152.
41. Wei CJ, Augusto E, Gomes CA et al. Regulation of fear responses by striatal and extrastriatal adenosine a(2a) receptors in forebrain. Biol Psychiatry 2014; 75 (11): 855-863.
42. Tavares AAD, Batis J, Barret O et al. In vivo evaluation of i-123 mni-420: A novel single photon emission computed tomography radiotracer for imaging of adenosine2a receptors in brain. Nucl Med Biol 2013; 40 (3): 403-409.
43. Saki M, Yamada K, Koshimura E, Sasaki K, Kanda T. In vitro pharmacological profile of the a(2a) receptor antagonist istradefylline. Naunyn- Schmiedebergs Arch Pharmacol 2013; 386 (11): 963-972.
44. Samsonsen C, Brathen G, Reimers A, Helde G, Brodtkorb E. Is dietary caffeine involved in seizure precipitation? Epilepsy Behav 2013; 28 (2): 147-150.
45. Fronz U, Deten A, Baumann F et al. Continuous adenosine a(2a) receptor antagonism after focal cerebral ischemia in spontaneously hypertensive rats. Naunyn-Schmiedebergs Arch Pharmacol 2014; 387 (2): 165-173.
46. Walaschewski R, Begrow F, Verspohl EJ. Impact and benefit of a2b- adenosine receptor agonists for the respiratory tract: Mucociliary clearance, ciliary beat frequency, trachea muscle tonus and cytokine release. J Pharm Pharmacol 2013; 65 (1): 123-132.
47. Hayallah AM, Elgaher WA, Salem OI, Alim A. Design and synthesis of some new theophylline derivatives with bronchodilator and antibacterial activities. Arch Pharm Res 2011; 34 (1): 3-21.
48. VanHaitsma TA, Mickleborough T, Stager JM, Koceja DM, Lindley MR, Chapman R. Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise in asthmatic athletes. Int J Sports Med 2010; 31 (4): 231-236.
49. Alafeefy AM, Alqasoumi SI, Hamid SGA et al. Synthesis and hypoglycemic activity of some new theophylline derivatives. J Enzym Inhib Med Chem 2014; 29 (3): 443-48.
50. Gibson CM, Fowler PW. Aromaticity of caffeine, xanthine and the dimethyl xanthines. Tetrahedron Lett 2014; 55 (13): 2078-2081.
51. Swift B, McGinn R, Gagnon D, Crandall CG, Kenny GP. Adenosine receptor inhibition attenuates the decrease in cutaneous vascular conductance during whole-body cooling from hyperthermia. Exp Physiol 2014; 99 (1): 196-204.
52. Szadujkis-Szadurska K, Grzesk G, Szadujkis-Szadurski L, Gajdus M, Matusiak G. Role of acetylcholine and calcium ions in three vascular contraction models: Angiotensin ii, phenylephrine and caffeine. Exp Ther Med 2012; 4 (2): 329-333.
53. Glatter KA, Myers R, Chiamvimonvat N. Recommendations regarding dietary intake and caffeine and alcohol consumption in patients with cardiac arrhythmias: What do you tell your patients to do or not to do? Curr Threat Options Cardiovasc Med 2012; 14 (5): 529-535.
54. Cummings KJ, Commons KG, Trachtenberg FL, Li A, Kinney HC, Nattie EE. Caffeine improves the ability of serotonin-deficient (pet-1-/-) mice to survive episodic asphyxia. Pediatr Res 2013; 73 (1): 38-45.
55. Golembiowska K, Dziubina A. The effect of adenosine a(2a) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of vmat2. Neurotox Res 2012; 22 (2): 150-157.
56. Shin HJ, Ryu JH, Kim ST, Zuo Z, Do SH. Caffeine-induced inhibition of the activity of glutamate transporter type 3 expressed in xenopus oocytes. Toxicol Lett 2013; 217 (2): 143-148.
57. Petzer A, Pienaar A, Petzer JP. The interactions of caffeine with monoamine oxidase. Life Sci 2013; 93 (7): 283-287.
58. Petzer A, Grobler P, Bergh JJ, Petzer JP. Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues. J Pharm Pharmacol 2014; 66 (5): 677-687.
59. Pohanka M, Dobes P. Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase. Int J Mol Sci 2013; 14: 9873-9882.
60. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap 2011; 155 (3): 219-229.
61. Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci 2012; 13 (2): 2219-2238.
62. Pohanka M. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. Int J Mol Sci 2014; 15 (6): 9809-9825.
63. Pohanka M. Butyrylcholinesterase as a biochemical marker, a review. Brat Med J 2013; 114 (12): 726-734.
64. Herman A, Herman AP. Caffeine's mechanisms of action and its cosmetic use. Skin Pharmacol Physiol 2013; 26 (1): 8-14.
65. Bhaskara S, Chandrasekharan MB, Ganguly R. Caffeine induction of cyp6a2 and cyp6a8 genes of drosophila melanogaster is modulated by camp and d-jun protein levels. Gene 2008; 415 (1-2): 49-59.
66. Puttachary S, Robertson AP, Clark CL, Martin RJ. Levamisole and ryanodine receptors. Ii: An electrophysiological study in ascaris suum. Mol Biochem Parasitol 2010; 171 (1): 8-16.
67. Gerasimova EV, Yakovleva OV, Zefirov AL, Sitdikova GF. Role of ryanodine receptors in the effects of hydrogen sulfide on transmitter release from the frog motor nerve ending. Bull Exp Biol Med 2013; 155 (1): 11-13.
68. Gaburjakova J, Gaburjakova M. Coupled gating modifies the regulation of cardiac ryanodine receptors by luminal ca(2+). Biochim Biophys Acta 2014; 1838 (3): 867-873.
69. Skiteva OI, Lapteva VI, Balezina OP. Role of stored calcium in the regulation of neurotransmitter quantum size. Bull Exp Biol Med 2012; 152 (4): 392-396.
70. Hotta S, Morimura K, Ohya S, Muraki K, Takeshima H, Imaizumi Y. Ryanodine receptor type2 deficiency changes excitation-contraction coupling and membrane potential in urinary bladder smooth muscle. J Physiol 2007; 582 (Pt 2): 489-506.
71. Arnaiz-Cot JJ, Damon BJ, Zhang XH et al. Cardiac calcium signalling pathologies associated with defective calmodulin regulation of type 2 ryanodine receptor. J Physiol-London 2013; 591 (17): 4287-4299.
72. Shou QY, Pan SZ, Tu J et al. Modulation effect of smilax glabra flavonoids on ryanodine receptor mediated intracellular ca2+ release in cardiomyoblast cells. J Ethnopharmacol 2013; 150 (1): 389-392.
73. Friedrich O, Yi B, Edwards JN et al. IL-1 alpha reversibly inhibits skeletal muscle ryanodine receptor a novel mechanism for critical illness myopathy? Am J Respir Cell Mol Biol 2014; 50 (6): 1096-1106.
74. Soner BC, Murat N, Guven H, Gidener S. The role of calcium entry on the relaxation response of rho-kinase inhibitor in rabbit renal artery. Brat Med J 2013; 114 (5): 258-261.
75. Ceraets L, Moonen HJ, Wouters EF, Bast A, Hageman GJ. Caffeine metabolites are inhibitors of the nuclear enzyme poly(adp-ribose)poly- merase-1 at physiological concentrations. Biochem Pharmacol 2006; 72 (7): 902-910.
76. Chen JC, Hwang JH, Chiu WH, Chan YC. Tetrandrine and caffeine modulated cell cycle and increased glioma cell death via caspase-dependent and caspase-independent apoptosis pathways. Nutr Cancer 2014; 66 (4): 700-706.
77. Kumala S, Fujarewicz K, Jayaraju D, Rzeszowska-Wolny J, Hancock R. Repair of DNA strand breaks in a minichromosome in vivo: Kinetics, modeling, and effects of inhibitors. PLoS One 2013; 8 (1): e52966.
78. Gervasini G, Ghotbi R, Aklillu E et al. Haplotypes in the 5'-untranslated region of the cyp1a2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. Environ Mol Mutagen 2013; 54 (2): 124-132.
79. Woziwodzka A, Gwizdek-Wisniewska A, Piosik J. Caffeine, pentoxifylline and theophylline form stacking complexes with iq-type heterocyclic aromatic amines. Bioorg Chem 2011; 39 (1): 10-17.
80. Osowski A, Pietrzak M, Wieczorek Z, Wieczorek J. Natural compounds in the human diet and their ability to bind mutagens prevents DNA-mutagen intercalation. J Toxicol Environ Health A 2010; 73 (17-18): 1141-1149.
81. Vukcevic NP, Babic G, Segrt Z, Ercegovic GV, Jankovic S, Acimovic L. Severe acute caffeine poisoning due to intradermal injections: Mesotherapy hazard. Vojnosanit Pregl 2012; 69 (8): 707-713.
82. Vukcevic NP, Babic G, Segrt Z, Ercegovic GV, Jankovic S, Acimovic L. Severe acute caffeine poisoning due to intradermal injections: Mesotherapy hazard (vol 69, pg 707, 2012). Vojnosanit Pregl 2012; 69 (10): 929-929.
83. Banerjee P, Ali Z, Levine B, Fowler DR. Fatal caffeine intoxication: A series of eight cases from 1999 to 2009. J Forensic Sci 2014; 59 (3): 865-868.
84. Jabbar SB, Hanly MG. Fatal caffeine overdose a case report and review of literature. Am J Forensic Med Pathol 2013; 34 (4): 321-324.
85. Sereshti H, Samadi S. A rapid and simple determination of caffeine in teas, coffees and eight beverages. Food Chem 2014; 158: 8-13.
86. Warszawski D, Gorodischer R, Kaplanski J. Comparative toxicity of caffeine and aminophylline (theophylline ethylenediamine) in young and adult rats. Biol Neonate1978; 34 (1-2): 68-71.
87. Tawde SN, Pushner B, Albin T, Stump S, Poppenga RH. Death by caffeine: Presumptive malicious poisoning of a dog by incorporation in ground meat. J Med Toxicol 2012; 8 (4): 436-440.
88. Moore MT, Greenway SL, FArris JL, Guerra B. Assessing caffeine as an emerging environmental concern using conventional approaches. Arch Environ Contam Toxicol 2008; 54 (1): 31-35.
89. Seifert SM, Seifert SA, Schaechter JL et al. An analysis of energydrink toxicity in the national poison data system. Clin Toxicol (Phila) 2013; 51 (7): 566-574.
90. Rodriguez RS, Haugen R, Rueber A, Huang CC. Reversible neuronal and muscular toxicity of caffeine in developing vertebrates. Comp Biochem Physiol C-Toxicol Pharmacol 2014; 163: 47-54.
91. Yeh CH, Liao YF, Chang CY et al. Caffeine treatment disturbs the angiogenesis of zebrafish embryos. Drug Chem Toxicol 2012; 35 (4): 361-365.
92. Tan Y, Liu J, Deng Y et al. Caffeine-induced fetal rat over-exposure to maternal glucocorticoid and histone methylation of liver igf-1 might cause skeletal growth retardation. Toxicol Lett 2012; 214 (3): 279-287.
93. Nikoui V, Ostadhadi S, Takzare N, Nabavi SM, Giorgi M, Bakhtiarian A. The role of clomipramine in potentiating the teratogenic effects of caffeine in pregnant rats: A histopathological study. ScientificWoldJournal 2013; 2013: 382-434.
94. Stanton CK, Gray RH. Effects of caffeine consumption on delayed conception. Am J Epidemiol1995; 142 (12): 1322-1329.
95. Kuczkowski KM. Caffeine in pregnancy. Arch Gynecol Obstet 2009; 280 (5): 695-698.
96. Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcome. Cochrane Database Syst Rev 2013; 2: CD006965.
97. Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Caffeinated and alcoholic beverage intake in relation to ovulatory disorder infertility. Epidemiology 2009; 20 (3): 374-381.
98. Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: Taking control of your fertility. Reprod Biol Endocrinol 2013; 11: 66.
99. Tournaye HJ, Cohlen BJ. Management of male-factor infertility. Best Pract Res Clin Obstet Gynaecol 2012; 26 (6): 769-775.
100. Homan G, Litt J, Norman RJ. The fast study: Fertility assessment and advice targeting lifestyle choices and behaviours: A pilot study. Hum Reprod 2012; 27 (8): 2396-2404.
101. Yamaguchi S, Funahashi H, Murakami T. Improved fertility in gilts and sows after artificial insemination of frozen-thawed boar semen by supplementation of semen extender with caffeine and cacl2. J Reprod Dev 2009; 55 (6): 645-649.
102. Nehlig A. Is caffeine a cognitive enhancer? J Alzheimer Dis 2010; 20 (Supplì): S85-94.
103. Lachance MP. The pharmacology and toxicology of caffeine. J Food Safe1982; 4 (2): 71-112.
104. Porciuncula LO, Sallaberry C, Mioranzza S, Botton PH, Rosemberg DB. The janus face of caffeine. Neurochem Int 2013; 63 (6): 594-609.
105. Chu YF, Chang WH, Black RM et al. Crude caffeine reduces memory impairment and amyloid beta(1-42) levels in an alzheimer's mouse model. Food Chem 2012; 135 (3): 2095-2102.
106. Vila-Luna S, Cabrera-Isidoro S, Vila-Luna L et al. Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrities in ca1 hippocampal neurons Neuroscience 2012; 202: 384-395.
107. Pohanka M. Alzheimers disease and oxidative stress. A review. Curr Med Chem 2013; 21 (3): 356-364.
108. Rivera-Oliver M, Diaz-Rios M. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: A review. Life Sci 2014; 101 (1-2): 1-9.
109. Knight JR. Remedy for migraine headache. Ca2826019 a1.2012.
110. Destrebecq A, Terzoni S, Sala E. Post-lumbar puncture headache: A review of issues for nursing practice. J Neurosci Nurs 2014; 46 (3): 180-186.
111. Duff M, Elkhodair S. Caffeine in the treatment of post lumbar puncture headache. Emerg Med J 2010; 27 (6): 477-477.
112. Elkhodair S, Duff M. Caffeine in the prophylaxis of post lumbar puncture headache Emerg Med J 2010; 27 (6): 476-477.
113. Grasela J, Schupp J, Nacht S. Anti-cellulite composition and method of treating cellulite. Us 2013/0 210840 a1. 2013.
114. Doherty J, Apong P, Akrong J, Shirazi S. Compositions and methods for promoting weight loss and increasing energy. Ca2747904 a1.2012.
115. Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and alzheimer's disease. J Alzheimer Dis 2010; 20 (S1): 167-174.
116. Chu YF, Chen Y, Brown PH, Lyle BJ. Coffee extracts as ingredients of foods, drugs, cosmetics, dietary supplements, and biologics. Us 2013/0261136 a1.2013.
117. Hirsbrunner P, Pavillard B. Purification of caffeine, us4758662. 1988.
118. Bailey DT, Yuhasz RL, Zheng B . Method for isolation of caffeine-free catechins from green tea; us6210679b1. 2001.
119. Roselius L, Kurzhais HA, Hubert P. Method for the selective extraction of caffeine from vegeable materials; us4 255458. 1981.
120. Ogura Y, Ohishi S, Fukuda M, Takahashi H, Itaya E, Konishi A. Method for removing caffeine from caffeine-containing catechin compound composition; us 2014/0113011a1. 2014.
121. International FB, Caffeine electronic cigarette liquid. Cn 1019 26505 a. 2010.
122. Chauffard F, Enslen MYA, Tachon P. Sustained release microparticulate caffeine formulation; us 5700484 a. 1997.
123. Crain S, Crain WW, Crain SM, Crain M. Novel method to improve the safety and efficacy of caffeine. Us 20130197015 a1. 2013.
124. Qi H, Li SX. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of parkinson's disease. Geriatr Gerontol Int 2014; 14 (2): 430-439.
125. Concalves N, Simoes AT, Cunha RA, Almeida LP. Caffeine and adenosine a(2a) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of machado-joseph disease. Ann Neurol 2013; 73 (5): 655-666.
126. Golembiowska K, Wardas J, Noworyta-Sokolowska K, Kaminska K, Gorska A. Effects of adenosine receptor antagonists on the in vivo lps-induced inflammation model of parkinson's disease. Neurotox Res 2013; 24 (1): 29-40.
127. Payami H, Factor SA. Promise of pharmacogenomics for drug discovery, treatment and prevention of parkinson's disease. A perspective. Neurotherapeutics 2014; 11 (1): 111-116.
128. Sandford-Mifflin KK, Parshad R, Robbins JH. Irradiating cell culture with florescent light; adding caffeine, incubation; us573219a. 1998.
129. Kobal J, Melik Z, Cankar K, Strucl M. Cognitive and autonomic dysfunction in presymptomatic and early huntington's disease. J Neurol 2014; 261 (6): 1119-1125.
130. Simonin C, Duru C, Salleron J et al. Association between caffeine intake and age at onset in huntington's disease. Neurobiol Dis 2013; 58: 179-182.
131. Duru C, Simonin C, Richard F et al. Caffeine is a modifier of age at onset in huntington's disease. Mov Disord 2011; 26 (Suppl 2): S60-S61.
132. Marangoni M, Adalbert R, Janeckova L et al. Age-related axonal swellings precede other neuropathological hallmarks in a knock-in mouse model of huntington's disease. Neurobiol Aging 2014; 35 (10): 2382-2393.
133. Koutsis G, Karadima G, Kladi A, Panas M. Late-onset huntington's disease: Diagnostic and prognostic considerations. Parkinsonism Relat Disord 2014; 20 (7): 726-730.
134. Copper DE, Cheney LC. Basic caffeine derivatives; us 2688618. 1952.
135. Arcari G, Micheli P, Luini F, Scarponi U. Caffeine derivatives; us3975389. 1976.
136. Jimenez-Botello LC, Avila-Costa MR, Carillo-Ruiz JD, Correa-Basurto J, Picazo O, Querejeta-Villagomez E. Therapeutic potential of caffeine derivate 1-methylxanthine, as a2a adenosine receptor antagonist on striatopallidal pathway. Mov Disord 2010; 25: S636-S636.
137. Liang BT, Jacobson KA. Methods for protecting against cardiac ischemia by administering adenosine a2a receptor antagonists; us5859019. 1999.
138. Higley MJ, Sabatini BL. Competitive regulation of synaptic ca2+ influx by d2 dopamine and a 2a adenosine receptors. Nat Neurosci 2010; 13 (8): 958-U977.
139. Tanimura Y, Vaziri S, Lewis MH. Indirect basal ganglia pathway mediation of repetitive behavior: Attenuation by adenosine receptor agonists. Behav Brain Res 2010; 210 (1): 116-122.
140. Lazarus M, Shen HY, Cherasse Y et al. Arousal effect of caffeine depends on adenosine a(2a) receptors in the shell of the nucleus accum- bens. The Journal of neuroscience: the official journal of the Society for Neuroscience 2011; 31 (27): 10067-10075.
141. Cronstein BN, Chan E. Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver; us 6555545 b2. 2003.
142. Ivachtchenko AV, Mitkin OD, Kadieva MG, M. OI. Substituted phenoxyacetic acids and esters and amides thereof, comprising a2, 6-dioxo-2, 3, 6, 7-tetrahydro-1H-purine-8-yl fragment and constituting a2a adenosine receptor antagonists, and the use thereof; wo 2013058681a3. 2012.
143. Palle V, Ramadas V, Barawkar D et al. Substituted fused pyrimidine compounds; wo2010103547 a2.2010.
144. Grzelak M, Hunter JC, Pond A, Varty G. Adenosine a2a receptor antagonists for the treatemnt of extra-pyramidal syndrome and other movement disorders; wo2007038212a1.2007.
145. Suzuki F, Shimada J, Koike N et al. Therapeutic agents for parkinson's disease; ep0590919a1. 1993.
146. Clemens KE, Quednau I, Heller AR, Klaschik E. Impact of cafe- drine/theodrenaline (akrinor(r)) on therapy of maternal hypotension during spinal anesthesia for cesarean delivery: A retrospective study. Minerva Ginecol 2010; 62 (6): 515-524.
147. Strumper D, Gogarten W, Durieux ME, Hartleb K, Van Aken H, Marcus MA. Effects of cafedrine/theodrenaline, etilefrine and ephedrine on uterine blood flow during epidural-induced hypotension in pregnant sheep. Fetal Diagn Ther 2005; 20 (5): 377-382.
148. Koch T, Wenzel V. Old drugs and new approval procedures: Akrinor remains marketable and an application for reapproval of arginin vasopressin has been made. Anaesthesist 2006; 55 (6): 708-710.
149. Uschenko T, Foellner S, Gruendling M et al. Akrinor-induced relaxation of pig coronary artery in vitro is transformed into alpha1-ad- renoreceptor-mediated contraction by pretreatment with propranolol. J Cardiovasc Pharmacol 2006; 47 (3): 450-455.